DT-6, a potent TGF-β1 inhibitor, impedes M2 macrophage-induced epithelial-to-mesenchymal transition and the invasive migration of cancer cells, thereby showing potential for cancer research applications [1].

DT-6, at concentrations ranging from 0.1-50 μM for 0-18 hours, reduced the protein expression of TGF-β1 in various cell lines, including THP-1, BV2, A549, MCF-7, U87, and HepG2 [1]. Additionally, a 50 μM dose of DT-6 over a 24-hour period decreased the secretion of TGF-β1 in M2 macrophages cultured in conditioned medium (CM) [1]. Furthermore, at 20 μM and 50 μM for 24 and 48 hours, DT-6 inhibited the ability of M2 macrophages to induce epithelial-to-mesenchymal transition (EMT) and the invasive migration of cancer cells by reducing the secretion of TGF-β1 [1].